Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500

Bulletin Express

2025/11/04

Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.

According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.

No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1179831478"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179831478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179831478?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179831478","market":"hk","top_or_hot":-1,"title":"Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500","media":"Bulletin Express","content":"<p>Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.</p>\n<p>According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.</p>\n<p>No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-04 17:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.</p>\n<p>According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.</p>\n<p>No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02192","symbol_name":"医脉通","start_time":0,"source_url":"","article_id":"1179831478","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179831478","pubTimestamp":1762249352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02192":"医脉通"},"translate_title":"Medlive Technology(02192)发布2025年10月月报表已发行股份增加53.45万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02192":1},"content_text":"Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.\nAccording to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.\nNo changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}